Vav, a protein with multiple signaling domains;La proteine Vav, une mosaique de domaines de signalisation

Medecine/Sciences

Volumn 13, Issue 5, 1997, Pages 629-638

  Romero, Francisco ^a   Dusanter Fourt, Isabelle ^a   Fischer, Siegmund ^a  

^a université Paris Cité   (France)

Author keywords

[No Author keywords available]

Indexed keywords

LEUCINE ZIPPER PROTEIN; ONCOPROTEIN; PLECKSTRIN;

ARTICLE; B LYMPHOCYTE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MOUSE MUTANT; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTO ONCOGENE; RECEPTOR BINDING; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE;

EID: 0030927274     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.4267/10608/430     Document Type: Article

References (45)

1. Katzav S, Martin-Zanca D, Barbacid M. Vav, a novel human oncogene derived from a locus ubiquitously expressed in hematopoietic cells. EMBO J 1989 ; 8 : 2283-90.
2. Coppola J, Bryant S, Koda T, Conway D, Barbacid M. Mechanism of activation of the Vav protooncogene. Cell Growth Differ 1991 ; 2: 95-105.
3. Katzav S, Cleveland JL, Heslop HE, Pulido D. Loss of the amino-terminal helix-loop-helix domain of the Vav proto-oncogene activates its transforming potential. Mol Cell Biol 1991 ; 11: 1912-20.
4. Adams JM, Houston H, Allen J, Lints T, Harvey R. The hematopoietically expressed Vav proto-oncogene shares homology with the db1 GDP-GTP exchange factor, the Bcr gene and a yeast gene (CDC24) involved in cytoskeletal organization. Oncogene 1992; 7: 611-8.
5. Bustelo XR, Rubin SD, Suen KL, Carrasco D, Barbacid M. Developmental expression of the Vav protooncogene. Cell Growth Differ 1993; 4: 297-308.
6. Henske EP, Short MP, Jozwiak S, Bovey CM, Ramlakhan S, Haines JL, Kwiatkowski DJ. Identification of VAV2 on 9q34 and its exclusion as the tuberous sclerosis gene TSC1. Ann Hum Genet 1995; 59: 25-37.
7. Martinerie C, Cannizzaro LA, Croce CM, Huebner K, Katzav S, Barbacid M. The human VAV proto-oncogene maps to chromosome region 19p12-19p13.2. Hum Genet 1990; 86: 65-8.
8. Castresana J, Saraste M. Does Vav bind to F-actin through a CH domain? FEBS Lett 1995; 374: 149-51.
9. Galland F, Birnbaum D. Le proto-oncogène mcf2/dbl et les facteurs d'échange GDP-GTP. Med Sci 1992; 8: 819-26.
10. Gulbins E, Coggeshall KM, Baier G, Katzav S, Burn P, Altman A. Tyrosine kinase-stimulated guanine nucleotide exchange activity of Vav in T cell activation. Science 1993; 260: 822-5.
11. Gulbins E, Coggeshall KM, Langlet C, Baier G, Bonnefoy-Berard N, Burn P, Wittinghofer A, Katzav S, Altman A. Activation of Ras in vitro and in intact fibroblasts by the Vav guanine nucleotide exchange protein. Mol Cell Biol 1994; 14: 906-13.
12. Bustelo XR, Suen KL, Leftheris K, Meyers CA, Barbacid M. Vav cooperates with Ras to transform rodent fibroblasts but is not a Ras GDP/GTP exchange factor. Oncogene 1994; 9: 2405-13.
13. Musacchio A, Gibson T, Rice P, Thompson J, Saraste M. The PH domain: a common piece in the structural patchwork of signalling proteins. Trends Biochem Sci 1993; 18: 343-8.
14. Gulbins E, Coggeshall KM, Baier G, Telford D, Langlet C, Baier-Bitterlich G, Bonnefoy-Berard N, Burn P, Wittinghofer A, Altman A. Direct stimulation of Vav guanine nucleotide exchange activity for Ras by phorbol esters and diglycerides. Mol Cell Biol 1994; 14: 4749-58.
15. Clevenger CV, Ngo W, Sokol DL, Luger SM, Gewirtz AM. Vav is necessary for prolactin-stimulated proliferation and is translocated into the nucleus of a T-cell line. J Biol Chem 1995; 270: 13246-53.
16. Cussac D, Frech M, Chardin P. Binding of the Grb2 SH2 domain to phosphotyrosine motifs does not change the affinity of its SH3 domains for Sos proline-rich motifs. EMBO J 1994; 13: 4011-21.
17. Vav/heterogeneous ribonucleoprotein K interaction. J Biol Chem 1994; 269: 20225-8.
18. Bustelo XR, Suen KL, Michael WM, Dreyfuss G, Barbacid M. Association of the Vav proto-oncogene product with poly(rC)-specific RNA-binding proteins. Mol Cell Biol 1995; 15: 1324-32.
19. Vav associates with the nuclear protein Ku-70. Mol Cell Biol 1996; 16: 37-44.
20. Hobert O, Schilling JW, Beckerle MC, Ullrich A, Jallal B. SH3 domain-dependent interaction of the proto-oncogene product Vav with the focal contact protein zyxin. Oncogene 1996; 12: 1577-81.
21. Ramos-Morales F, Romero F, Schweighoffer F, Bismuth G, Camonis J, Tortolero M, Fischer S. The proline-rich region of Vav binds to Grb2 and Grb3-3. Oncogene 1995; 11: 1665-9.
22. Ye ZS, Baltimore D. Binding of Vav to Grb2 through dimerization of Src homology 3 domains. Proc Natl Acad Sci USA 1994; 91: 12629-33.
23. Bustelo XR, Barbacid M. Tyrosine phosphorylation of the Vav proto-oncogene product in activated B cells. Science 1992; 256: 1196-9.
24. Bustelo XR, Ledbetter JA, Barbacid M. Product of Vav proto-oncogene defines a new class of tyrosine protein kinase substrates. Nature 1992; 356: 68-71.
25. Songyang Z, Shoelson SE, McGlade J, Olivier P, Pawson T, Bustelo XR, Barbacid M, Sabe H, Hanafusa H, Yi T, Cantley LC. Specific motifs recognized by the SH2 domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk, and Vav. Mol Cell Biol 1994; 14: 2777-85.
26. Margolis B, Hu P, Katzav S, Li W, Oliver JM, Ullrich A, Weiss A, Schlessinger J. Tyrosine phosphorylation of Vav proto-oncogene product containing SH2 domain and transcription factor motifs. Nature 1992; 356 : 71-4.
27. Katzav S, Sutherland M, Packham G, Yi T, Weiss A. The protein tyrosine kinase ZAP-70 can associate with the SH2 domain of proto-Vav. J Biol Chem 1994; 269: 32579-85.
28. BCR/ABL. EMBO J 1995; 14: 257-65.
29. Kon-Kozlowsky M, Pani G, Pawson T, Siminovitch KA. The tyrosine phosphatase PTP1C associates with Vav, Grb2, and mSos1 in hematopoietic cells. J Biol Chem 1996; 271: 3856-62.
30. Seidel-Dugan C, Meyer BE, Thomas SM, Brugge JS. Effects of SH2 and SH3 deletions on the functional activities of wild-type and transforming variants of c-Src. Mol Cell Biol 1992; 12: 1835-45.
31. Huby RD, Carlile GW, Ley SC. Interactions between the protein tyrosine kinase ZAP-70, the proto-oncoprotein Vav, and tubulin in Jurkat T cells. J Biol Chem 1995; 270: 30241-4.
32. Vav activity. Mol Cell Biol 1995; 15: 4337-46.
33. Gouy H, Debre P, Bismuth G. The proto-oncogene Vav product is constitutively tyrosine-phosphorylated in normal human immature T cells. Eur J Immunol 1995; 25: 3030-4.
34. Miura O, Miura Y, Nakamura N, Quelle FW, Witthuhn BA, Ihle JN, Aoki N. Induction of tyrosine phosphorylation of Vav and expression of Pim-1 correlates with Jak2-mediated growth signaling from the erythropoietin receptor. Blood 1994; 84: 4135-41.
35. Gupta S, Weiss A, Kumar G, Wang S, Nel A. The T-cell antigen receptor utilizes Lck, Raf-1, and MEK-1 for activating mitogen-activated protein kinase. Evidence for the existence of a second protein kinase C-dependent pathway in an Lck-negative Jurkat cell mutant. J Biol Chem 1994; 269: 17349-57.
36. Syk protein tyrosine kinase: efficient phosphorylation of motifs recognized by Src homology 2 domains of the Src family. FEBS Lett 1995; 367: 149-52.
37. Ramos-Morales F, Druker BJ, Fischer S. Vav binds to several SH2/SH3 containing proteins in activated lymphocytes. Oncogene 1994; 9: 1917-23.
38. Wulf GM, Adra CN, Lim B. Inhibition of hematopoietic development from embryonic stem cells by antisense Vav RNA. EMBO J 1993; 12: 5065-74.
39. Zmuidzinas A, Fischer KD, Lira SA, Forrester L, Bryant S, Bernstein A, Barbacid M. The Vav proto-oncogene is required early in embryogenesis but not for hematopoietic development in vitro. EMBO J 1995; 14: 1-11
40. + thymocytes. Nature 1995; 374: 474-7.
41. Tarakhovsky A, Turner M, Schaal S, Mee PJ, Duddy LP, Rajewsky K, Tybulewicz VL. Defective antigen receptor-mediated proliferation of B and T cells in the absence of Vav. Nature 1995; 374: 467-70.
42. Zhang R, Alt FW, Davidson L, Orkin SH, Swat W. Defective signalling through the T-and B-cell antigen receptors in lymphoid cells lacking the Vav proto-oncogene. Nature 1995; 374: 470-3.
43. Hobert O, Jallal B, Ullrich A. Interaction of Vav with ENX-1, a putative transcriptional regulator of homeobox gene expression. Mol Cell Biol 1996; 16: 3066-73.
44. Vav, in platelets. J Biol Chem 1996; 271: 7544-50.
45. Weng WK, Jarvis L, Le Bien TW. Signaling through CD19 activates Vav/mitogen-activated protein kinase pathway and induces formation of a CD19/Vav/phosphatidylinositol 3-kinase complex in human cell precursors. J Biol Chem 1994; 269: 32514-21.